Rocket Pharmaceuticals Inc
NASDAQ:RCKT
| Market Cap (Intraday) | 340.97M |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $3.25 |
| 50-Day MA | $3.16 |
| 200-Day MA | $7.02 |
Rocket Pharmaceuticals Inc Stock, NASDAQ:RCKT
9 Cedarbrook Drive, 350 5th Avenue, Cranbury, New Jersey 08512
United States of America
Phone: +1.609.659.8001
Number of Employees: 299
Description
Rocket Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the development of gene therapy treatment options for rare and devastating pediatric diseases. Its multi-platform development approach applies the lentiviral vector and adeno-associated viral vector gene therapy platforms. Its clinical program is an LVV-based gene therapy for the treatment of Fanconi Anemia (FA), a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer. The company was founded on July 7, 1999 and is headquartered in Cranbury, NJ.